These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 31299089)

  • 1. Effect of fragmentation of cancer care on treatment use and survival in hepatocellular carcinoma.
    Hester CA; Karbhari N; Rich NE; Augustine M; Mansour JC; Polanco PM; Porembka MR; Wang SC; Zeh HJ; Singal AG; Yopp AC
    Cancer; 2019 Oct; 125(19):3428-3436. PubMed ID: 31299089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of hospital safety net designation on treatment use and survival in hepatocellular carcinoma.
    Mokdad AA; Murphy CC; Pruitt SL; Mansour JC; Marrero JA; Singal AG; Yopp AC
    Cancer; 2018 Feb; 124(4):743-751. PubMed ID: 29072773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Provider Specialty and Multidisciplinary Care With Hepatocellular Carcinoma Treatment and Mortality.
    Serper M; Taddei TH; Mehta R; D'Addeo K; Dai F; Aytaman A; Baytarian M; Fox R; Hunt K; Goldberg DS; Valderrama A; Kaplan DE;
    Gastroenterology; 2017 Jun; 152(8):1954-1964. PubMed ID: 28283421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved Survival of Hepatocellular Carcinoma Patients Diagnosed with a Dedicated Screening Programme-a Propensity Score Adjusted Analysis.
    Chinnaratha MA; Campbell K; Mathias R; McCormick RJ; Woodman RJ; Wigg AJ
    J Gastrointest Cancer; 2019 Dec; 50(4):888-893. PubMed ID: 30345486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant transcatheter arterial chemoembolization does not provide survival benefit compared to curative therapy alone in single hepatocellular carcinoma.
    Yeh ML; Huang CI; Huang CF; Hsieh MY; Huang JF; Dai CY; Lin ZY; Chen SC; Yu ML; Chuang WL
    Kaohsiung J Med Sci; 2015 Feb; 31(2):77-82. PubMed ID: 25645985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-Time Adjusted Survival of Patients With Compensated Viral Cirrhosis: A Multi-Center Cohort Study.
    Costentin CE; Layese R; Bourcier V; Cagnot C; Marcellin P; Guyader D; Pol S; Larrey D; De Lédinghen V; Ouzan D; Zoulim F; Roulot D; Tran A; Bronowicki JP; Zarski JP; Riachi G; Calès P; Péron JM; Alric L; Bourlière M; Mathurin P; Blanc JF; Abergel A; Serfaty L; Mallat A; Grangé JD; Attali P; Bacq Y; Wartelle C; Dao T; Thabut D; Pilette C; Silvain C; Christidis C; Nguyen-Khac E; Bernard-Chabert B; Zucman D; Di Martino V; Sutton A; Letouzé E; Imbeaud S; Zucman-Rossi J; Audureau E; Roudot-Thoraval F; Nahon P;
    Gastroenterology; 2018 Aug; 155(2):431-442.e10. PubMed ID: 29729258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma.
    Cabibbo G; Petta S; Barbara M; Attardo S; Bucci L; Farinati F; Giannini EG; Negrini G; Ciccarese F; Rapaccini GL; Di Marco M; Caturelli E; Zoli M; Borzio F; Sacco R; Virdone R; Marra F; Mega A; Morisco F; Benvegnù L; Gasbarrini A; Svegliati-Baroni G; Foschi FG; Olivani A; Masotto A; Nardone G; Colecchia A; Persico M; Craxì A; Trevisani F; Cammà C;
    J Hepatol; 2017 Jul; 67(1):65-71. PubMed ID: 28192185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination transarterial chemoembolization and radiofrequency ablation therapy for early hepatocellular carcinoma.
    Song MJ; Bae SH; Lee JS; Lee SW; Song DS; You CR; Choi JY; Yoon SK
    Korean J Intern Med; 2016 Mar; 31(2):242-52. PubMed ID: 26874512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trends in epidemiology, treatment, and survival of hepatocellular carcinoma patients between 1998 and 2009: an analysis of 1066 cases of a German HCC Registry.
    Weinmann A; Koch S; Niederle IM; Schulze-Bergkamen H; König J; Hoppe-Lotichius M; Hansen T; Pitton MB; Düber C; Otto G; Schuchmann M; Galle PR; Wörns MA
    J Clin Gastroenterol; 2014 Mar; 48(3):279-89. PubMed ID: 24045276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of body mass index on survival after curative therapy for non-B non-C hepatocellular carcinoma.
    Nishikawa H; Osaki Y; Takeda H; Sakamoto A; Saito S; Nishijima N; Nasu A; Arimoto A; Kita R; Kimura T
    J Gastrointestin Liver Dis; 2013 Jun; 22(2):173-81. PubMed ID: 23799216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Childhood liver tumors in Argentina: Incidence trend and survival by treatment center. A report from the national pediatric cancer registry, ROHA network 2000-2015.
    Moreno F; Rose A; Chaplin MA; Cipolla MC; García Lombardi M; Nana M; Cervio G; Halac E; Viso M; Ayarzabal V; Bosaleh A; Liberto D; Sarabia E; Rizzi A; Morici M; Streitenberger P; de Dávila MTG
    Pediatr Blood Cancer; 2020 Nov; 67(11):e28583. PubMed ID: 32737960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transarterial Chemoembolization versus Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma after Resection within Barcelona Clinic Liver Cancer Stage 0/A: A Retrospective Comparative Study.
    Chen R; Gan Y; Ge N; Chen Y; Wang Y; Zhang B; Wang Y; Ye S; Ren Z
    J Vasc Interv Radiol; 2016 Dec; 27(12):1829-1836. PubMed ID: 27553917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment Optimization for Hepatocellular Carcinoma in Elderly Patients in a Japanese Nationwide Cohort.
    Kaibori M; Yoshii K; Hasegawa K; Ogawa A; Kubo S; Tateishi R; Izumi N; Kadoya M; Kudo M; Kumada T; Sakamoto M; Nakashima O; Matsuyama Y; Takayama T; Kokudo N;
    Ann Surg; 2019 Jul; 270(1):121-130. PubMed ID: 29608544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management and outcomes among patients with sarcomatoid hepatocellular carcinoma: A population-based analysis.
    Wu L; Tsilimigras DI; Farooq A; Hyer JM; Merath K; Paredes AZ; Mehta R; Sahara K; Shen F; Pawlik TM
    Cancer; 2019 Nov; 125(21):3767-3775. PubMed ID: 31299092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Racial and Ethnic Differences in Presentation and Outcomes of Hepatocellular Carcinoma.
    Rich NE; Hester C; Odewole M; Murphy CC; Parikh ND; Marrero JA; Yopp AC; Singal AG
    Clin Gastroenterol Hepatol; 2019 Feb; 17(3):551-559.e1. PubMed ID: 29859983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Racial/ethnic disparities in access to care and survival for patients with early-stage hepatocellular carcinoma.
    Mathur AK; Osborne NH; Lynch RJ; Ghaferi AA; Dimick JB; Sonnenday CJ
    Arch Surg; 2010 Dec; 145(12):1158-63. PubMed ID: 21173289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Older Patients With Hepatocellular Carcinoma Have More Advanced Disease, Lower Rates of Treatment, and Lower Survival.
    Yan M; Ha J; Aguilar M; Liu B; Frenette CT; Bhuket T; Wong RJ
    J Clin Gastroenterol; 2017 Apr; 51(4):378-383. PubMed ID: 27380460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and prognostic implications of pretreatment albumin to C-reactive protein ratio in patients with hepatocellular carcinoma.
    Wu MT; He SY; Chen SL; Li LF; He ZQ; Zhu YY; He X; Chen H
    BMC Cancer; 2019 Jun; 19(1):538. PubMed ID: 31164099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transarterial chemoembolization versus hepatic resection in hepatocellular carcinoma treatment: a meta-analysis.
    Tian X; Dai Y; Wang DQ; Zhang L; Sui CG; Meng FD; Jiang SY; Liu YP; Jiang YH
    Drug Des Devel Ther; 2015; 9():4431-40. PubMed ID: 26309396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of socioeconomic status on outcomes in hepatocellular carcinoma: Inferences from primary insurance.
    Sellers CM; Uhlig J; Ludwig JM; Taddei T; Stein SM; Lim JK; Kim HS
    Cancer Med; 2019 Oct; 8(13):5948-5958. PubMed ID: 31436905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.